SCHEMBL22497169

SCHEMBL22497169

CC(Cn1cnc(S(N)(=O)=O)n1)OCc1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 4/20 0.38
▸ CA2 P00918 4/20 0.38
▸ CA9 Q16790 4/20 0.38
▸ CA12 O43570 3/20 0.38
▸ CA7 P43166 2/20 0.38
▸ CA4 P22748 1/20 0.38
▸ CA5A P35218 1/20 0.38
▸ CA5B Q9Y2D0 1/20 0.38
▸ PKM P14618 1/20 0.33
▸ GGT1 P19440 1/20 0.33
▸ SLC1A3 P43003 2/20 0.33
▸ SLC1A2 P43004 2/20 0.33
▸ SLC1A1 P43005 2/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ ALOX5 P09917 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22497167 1.00 CA1 (0.38) CA1CA2CA9CA12CA7
SCHEMBL22497223 0.74 RAB9A (0.49) MEN1KMT2A
SCHEMBL22497225 0.74 RAB9A (0.49) MEN1KMT2A
SCHEMBL22497293 0.73 CA2 (0.37) CA1CA2CA9CA12CA7
SCHEMBL22497291 0.73 CA2 (0.37) CA1CA2CA9CA12CA7
SCHEMBL14461627 0.65 GSK3A (0.49) GGT1SLC1A3SLC1A2SLC1A1MEN1
SCHEMBL18740977 0.64 CA1 (0.42) CA1CA2CA9SLC1A3SLC1A2
SCHEMBL6271578 0.64 TSHR (0.44) CA1CA2CA9SLC1A3SLC1A2
SCHEMBL17049557 0.64 PSMB5 (0.48) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL7864015 0.64 IDO1 (0.46) SLC1A3SLC1A2SLC1A1MEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12012392-B2 Sulfonamide carboxamide compounds INFLAZOME LIMITED (IE) 2024-06-18 — — US disclosed
US-20200317637-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LIMITED (IE) 2020-10-08 — — US disclosed
CN-111315733-A Novel sulfonamide carboxamide compounds 英夫拉索姆有限公司 2020-06-19 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200317637-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS NLRP3, NOD1, PYCARD CA1 2846/4885CA2 453/4885CA9 2347/4885
US-12012392-B2 Sulfonamide carboxamide compounds NLRP3, PYCARD, NOD1 CA1 2208/4885CA2 311/4885CA9 1798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback